학술논문

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial.
Document Type
Journal Article
Source
JAMA: Journal of the American Medical Association. 1/15/2019, Vol. 321 Issue 2, p156-164. 9p.
Subject
*FECAL microbiota transplantation
*ULCERATIVE colitis
*THERAPEUTICS research
*DISEASE remission
*TREATMENT effectiveness
*AUTOGRAFTS
*BIOCHEMISTRY
*COLONOSCOPY
*COMPARATIVE studies
*ENEMA
*HOMOGRAFTS
*PHENOMENOLOGY
*RESEARCH methodology
*MEDICAL cooperation
*METABOLISM
*RESEARCH
*EVALUATION research
*RANDOMIZED controlled trials
*BLIND experiment
*THERAPEUTICS
Language
ISSN
0098-7484
Abstract
Importance: High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity.Objective: To assess the efficacy of a short duration of FMT therapy to induce remission in UC using anaerobically prepared stool.Design, Setting, and Participants: A total of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-blind clinical trial in 3 Australian tertiary referral centers between June 2013 and June 2016, with 12-month follow-up until June 2017.Interventions: Patients were randomized to receive either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up for 12 months.Main Outcomes and Measures: The primary outcome was steroid-free remission of UC, defined as a total Mayo score of ≤2 with an endoscopic Mayo score of 1 or less at week 8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes included adverse events.Results: Among 73 patients who were randomized (mean age, 39 years; women, 33 [45%]), 69 (95%) completed the trial. The primary outcome was achieved in 12 of the 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous FMT (difference, 23% [95% CI, 4%-42%]; odds ratio, 5.0 [95% CI, 1.2-20.1]; P = .03). Five of the 12 participants (42%) who achieved the primary end point at week 8 following donor FMT maintained remission at 12 months. There were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group.Conclusions and Relevance: In this preliminary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety.Trial Registration: anzctr.org.au Identifier: ACTRN12613000236796. [ABSTRACT FROM AUTHOR]